跳至主要内容
临床试验/NCT04507776
NCT04507776已完成不适用

Long Term Adherence and Efficacy of Etanercept in SpA Iraqi Patients: 7 Year Data From Local Registry

Pfizer1 个研究点 分布在 1 个国家目标入组 763 人开始时间: 2020年9月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
Pfizer
入组人数
763
试验地点
1
主要终点
Percentage of Participants With 7 Years Adherence to Etanercept

研究概览

简要总结

This study is to evaluate local data in Iraqi patients with Spondyloarthropathies on Enbrel treatment with regards to efficacy and adherence using data from the Baghdad Teaching Hospital (Rheumatology Center)

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosed SpA patients
  • 18 years of age and older.
  • Did not receive previous other biological treatments.
  • Patients have at least 1 year on Enbrel.

排除标准

  • Had previously used another biological treatments.
  • Use of etanercept for less than 1 year duration.

研究组 & 干预措施

Patients with spondyloarthropathies

Patients with spondyloarthrosis that received Etanercept as treatment for disease

干预措施: Etanercept (Drug)

结局指标

主要结局

Percentage of Participants With 7 Years Adherence to Etanercept

时间窗: 7 years [from the data retrieved and observed in 1 month of this study]

In this outcome measure, percentage of participants who continued etanercept treatment and adhered to the treatment for 7 years were reported.

次要结局

未报告次要终点

研究者

发起方
Pfizer
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Study To Evaluate The Efficacy And Long-Term... | 临床试验